Theralase® Strengthens Its Patent Portfolio with an Additional US Patent Covering Metal-Glycoprotein Complexes, Including Rutherrin® Based Photo Dynamic Therapy, in Immune Privileged Sites
Toronto, Ontario – June 22, 2018
Inflammation, particularly at an immune-privileged site, induced by surgery, radiation or another anti-cancer modality may act as a “double edged sword”.
On the positive side, an increase in inflammation may help trigger the activation of the body’s innate immune response, used to help protect the body from cancer.
On the negative side, an increase in inflammation may also activate the function of intra-tumoural neutrophils and macrophages, whose role is to negate the body’s natural immune response, by minimizing the anti-cancer activity of CD8+ cytolytic T lymphocytes.
Therefore, it is critical to control the amount of inflammation within an immune privileged site to optimize the generation and proliferation of tumour specific CD8+ cytolytic T lymphocytes.
Arkady Mandel M.D., Ph.D., D.Sc., Interim Chief Executive Officer and Chief Scientific Officer, Theralase® stated that, “Our latest technology holds significant potential in the advancement of anti-cancer Photo Dynamic Therapy (“PDT”) and its associated immune response, in the destruction of cancer in immune privileged sites. I am pleased that the USPTO has issued a Notice of Allowance for the patent application that protects our advanced PDC formulations and the technology behind it.”
Dr. Mandel continued, “Theralase’s patented PDT approach currently enables the delivery of PDCs inside cancer cells targeting tumours and has now advanced to encompass immune-privileged sites. The Company continues to build its patent portfolio for its anti-cancer division, providing enhanced protection from competition, as the Company advances towards commercialization of this technology through the clinical study process. A comprehensive intellectual property portfolio provides added security for investors and potential partners, as we embark on the pivotal phase of clinical development, with our Phase II clinical study for Non-Muscle Invasive Bladder Cancer, as well as working on the regulatory path for a Phase Ib clinical study in Glio Blastoma Multiforme (“GBM”) brain cancer.”
Theralase Technologies Inc. (“Theralase®”) (TSXV: TLT) (TLTFF: OTC Pink®) in its Therapeutic Laser Technology Division designs, manufactures and markets patented super-pulsed laser technology indicated for the: elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy Division researches and develops specially designed molecules called Photo Dynamic Compounds, which are able to localize to the cancer cells and then when laser light activated, effectively destroy them.
About Theralase® Technologies Inc.
Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations to safely and effectively destroy various cancers. The Company in its Cool Laser Division designs, manufactures and distributes patented and proprietary super-pulsed cool laser technology for the treatment of knee pain, and in off-label use, the treatment of numerous nerve, muscle and joint conditions.
This news release contains “forward-looking statements” which reflect the current expectations of management of the Company’s future growth, results of operations, performance and business prospects and opportunities. Such statements include, but are not limited to, statements regarding the Company’s development and commercialization of the TLC-2000, including with respect to ongoing redesign work and regulatory clearance process for expanded claims and the Company’s development and commercialization strategy with respect to its Anti-Cancer Technology. Wherever possible, words such as “may“, “would“, “could“, “should”, “will“, “anticipate“, “believe“, “plan“, “expect“, “intend“, “estimate“, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions including with respect to the ability of the Company to successfully complete the redesign work under the proposed timeframe and scope of work or at all, the availability of financing to advance the development of the TLC-2000, the ability of the Company to secure further regulatory clearances (including with respect to expanded claims) from Health Canada and/ or the FDA with respect to the TLC-2000 under the proposed timeframe and scope or at all, the ability of the Company to achieve wider commercial distribution of the TLC-2000, the ability of the Company to execute its strategy with respect to its Anti-Cancer Technology, the ability of the Company to secure further regulatory approvals from Health Canada and/ or the FDA for its NMBIC clinical studies and the ability of the Company to finalize development of, and successfully commercialize, its Anti-Cancer Technology. Many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements; including, without limitation, those listed in the filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information: